Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseaseBladder CancerRenal Pelvic CarcinomaSubgroupICD10C65C67.-MeSHCarcinoma, Transitional CellUrinary Bladder NeoplasmsUrogenital NeoplasmsUrologic NeoplasmsSequenceCheckMate 901: NIVO360/GEMC1000/CISP70, Urinary Bladder Ca (PID2490) -|- NIVO480 Maint. (PID2491)JAVELIN Bladder 100: GEMC1000/CISP70, urinary bladder Ca (PID544) -|- AVEL800, maint. (PID679)NIVO360/GEMC1000/CRBP4,5, Urinary Bladder Ca (PID3256) or NIVO360/GEMC1000/OXAL130, Urinary Bladder Ca (PID3257) -|- NIVO480, maint. (PID3258)ChemotherapyChemo-substanceCarboplatinCisplatinGemcitabineNivolumabOxaliplatinPaclitaxelChemo-substanceCarboplatinCisplatinGemcitabineNivolumabOxaliplatinPaclitaxelChemo-substanceCarboplatinCisplatinGemcitabineNivolumabOxaliplatinPaclitaxelChemo-substanceCarboplatinCisplatinGemcitabineNivolumabOxaliplatinPaclitaxelNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances134710Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseMaintenanceTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlBleedingConstipationDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHyperglycemiaHypoalbuminemiaHypothyroidismIncrease AminotransferasesInfectionsLeukopeniaMucositisNeuropathyNeutropeniaPruritusRashRenal FailureThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorBellmunt JLi Zvan der Heijden MS von der Maase HDiseaselokal fortgeschrittenes oder metastasiertes Urothelkarzinom, ohne Vorbehandlung, ECOG 0-1TCC des Urothels, fortgeschr. oder metastasiert, ErstlinieUrothelkarzinom, fortgeschritten oder metastasiert, Cisplatin-ungeeignet, ErstlinieUrothelkarzinom, fortgeschritten oder metastasiert, Erstlinie, ECOG 0-1OriginArhus University Hospital, DänemarkIcahn School of Medicine at Mount Sinai, New York, New YorkNetherlands Cancer Institute, Amsterdam, CheckMate 901 TrialVall d’Hebron University Hospital and University Hospital del Mar, BarcelonaProtokolle in Überarbeitung 7 protocols foundGemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID544 V1.1)Nivolumab 360 / Gemcitabine 1000 / Carboplatin 4.5, Bladder Cancer (PID3256 V1.0)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70 - Nivolumab 480 Maintenance, Bladder Cancer (PID2491 V1.0)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID2490 V1.0)Nivolumab 360 / Gemcitabine 1000 / Oxaliplatin 130, Bladder Cancer (PID3257 V1.0)Nivolumab 480, Bladder Cancer, maintenance therapy (PID3258 V1.0)Paclitaxel 80 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID1359 V1.3)
